Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Randomized Phase II Evaluation of Iproplatin (CHIP) and Carboplatin (CBDCA) in Lung Cancer

A Southeastern Cancer Study Group Trial

Kramer, Barnett S., M.D.; Birch, Robert, Ph.D.; Greco, Anthony, M.D.; Prestridge, Karen; DeSimone, Philip, M.D.; Omura, George, M.D.

American Journal of Clinical Oncology: December 1988 - Volume 11 - Issue 6 - p 643–645
Original Article: PDF Only

Cisplatin-containing regimens have shown activity in both small and non-small cell lung cancer. We therefore conducted a randomized Phase II trial of the new platinum congeners iproplatin and carboplatin in bronchogenic carcinoma. The overall response rate in chemotherapy-naive non-small cell patients with iproplatin was 3/48 (6%; 95% confidence interval 2–18%) and with carboplatin 6/50 (12%; 95% confidence interval 5–25%). The response rates in previously treated small cell patients were 0/16 and 1/18, respectively. Overall, neither agent has pronounced activity in bronchogenic carcinoma.

From the University of Florida (B.S.K.), the University of Alabama at Birmingham (R.B., K.P., G.O.), Vanderbilt University (A.G.), and the University of Kentucky (P.DeS.).

© Lippincott-Raven Publishers.